254 related articles for article (PubMed ID: 30636588)
21. Cytotoxicity and Chemotherapeutic Potential of Natural Rosin Abietane Diterpenoids and their Synthetic Derivatives.
Faustino C; Neto Í; Fonte P; Macedo A
Curr Pharm Des; 2018; 24(36):4362-4375. PubMed ID: 30648502
[TBL] [Abstract][Full Text] [Related]
22. Antimitotic activity of structurally simplified biaryl analogs of the anticancer agents colchicine and combretastatin A4.
McNulty J; van den Berg S; Ma D; Tarade D; Joshi S; Church J
Bioorg Med Chem Lett; 2015 Jan; 25(1):117-21. PubMed ID: 25466200
[TBL] [Abstract][Full Text] [Related]
23. Recent Developments on Phenstatins as Potent Antimitotic Agents.
Chen X; Wang SM; Kumar GB; Bare GAL; Leng J; Bukhari SNA; Qin HL
Curr Med Chem; 2018; 25(20):2329-2352. PubMed ID: 29110592
[TBL] [Abstract][Full Text] [Related]
24. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum.
Pettit GR; Singh SB; Niven ML; Hamel E; Schmidt JM
J Nat Prod; 1987; 50(1):119-31. PubMed ID: 3598594
[TBL] [Abstract][Full Text] [Related]
25. [Natural organic compounds that affect to microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin].
Iwasaki S; Shirai R
Yakugaku Zasshi; 2000 Oct; 120(10):875-89. PubMed ID: 11082700
[TBL] [Abstract][Full Text] [Related]
26. The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design.
Giacomini E; Rupiani S; Guidotti L; Recanatini M; Roberti M
Curr Med Chem; 2016; 23(23):2439-89. PubMed ID: 27183980
[TBL] [Abstract][Full Text] [Related]
27. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers.
Rajak H; Dewangan PK; Patel V; Jain DK; Singh A; Veerasamy R; Sharma PC; Dixit A
Curr Pharm Des; 2013; 19(10):1923-55. PubMed ID: 23237054
[TBL] [Abstract][Full Text] [Related]
28. Natural products as antimitotic agents.
Dall'Acqua S
Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
[TBL] [Abstract][Full Text] [Related]
29. Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
Kanthou C; Tozer GM
Expert Opin Ther Targets; 2007 Nov; 11(11):1443-57. PubMed ID: 18028009
[TBL] [Abstract][Full Text] [Related]
30. Combretastatins: from natural products to drug discovery.
Cirla A; Mann J
Nat Prod Rep; 2003 Dec; 20(6):558-64. PubMed ID: 14700199
[TBL] [Abstract][Full Text] [Related]
31. Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach.
Soo E; Thakur S; Qu Z; Jambhrunkar S; Parekh HS; Popat A
J Colloid Interface Sci; 2016 Jan; 462():368-74. PubMed ID: 26479200
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of resveratrol-based nitrovinylstilbenes as antimitotic agents.
Reddy MA; Jain N; Yada D; Kishore C; Vangala JR; P Surendra R; Addlagatta A; Kalivendi SV; Sreedhar B
J Med Chem; 2011 Oct; 54(19):6751-60. PubMed ID: 21851083
[TBL] [Abstract][Full Text] [Related]
33. Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
Brown AW; Fisher M; Tozer GM; Kanthou C; Harrity JP
J Med Chem; 2016 Oct; 59(20):9473-9488. PubMed ID: 27690431
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
[TBL] [Abstract][Full Text] [Related]
35. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
36. Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo.
Meng J; Guo F; Xu H; Liang W; Wang C; Yang XD
Sci Rep; 2016 Mar; 6():22390. PubMed ID: 26947928
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimitotic agents.
Hamze A; Giraud A; Messaoudi S; Provot O; Peyrat JF; Bignon J; Liu JM; Wdzieczak-Bakala J; Thoret S; Dubois J; Brion JD; Alami M
ChemMedChem; 2009 Nov; 4(11):1912-24. PubMed ID: 19790205
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells.
Wang TT; Schoene NW; Kim YS; Mizuno CS; Rimando AM
Mol Nutr Food Res; 2010 Mar; 54(3):335-44. PubMed ID: 20077416
[TBL] [Abstract][Full Text] [Related]
39. Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.
Durrant DE; Richards J; Tripathi A; Kellogg GE; Marchetti P; Eleopra M; Grisolia G; Simoni D; Lee RM
Invest New Drugs; 2009 Feb; 27(1):41-52. PubMed ID: 18516499
[TBL] [Abstract][Full Text] [Related]
40. Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety.
Maya AB; Pérez-Melero C; Mateo C; Alonso D; Fernández JL; Gajate C; Mollinedo F; Peláez R; Caballero E; Medarde M
J Med Chem; 2005 Jan; 48(2):556-68. PubMed ID: 15658869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
